View of 35. EVALUATING THE RESULT LINE 1 OF TREATMENT NON SMALL CELL LUNG CANCER PATIENTS STAGE IV HABOR EGFR MUTATION BY OSIMERTINIB AT NATIONAL LUNG HOSPITAL FROM 2019 TO 2022

Return to Article Details 35. EVALUATING THE RESULT LINE 1 OF TREATMENT NON SMALL CELL LUNG CANCER PATIENTS STAGE IV HABOR EGFR MUTATION BY OSIMERTINIB AT NATIONAL LUNG HOSPITAL FROM 2019 TO 2022 Download Download PDF